SINOPHARM TECH(08156) released its interim results, with a net loss attributable to shareholders of 5.513 million Hong Kong dollars, an increase of 91.69% year-on-year.

Sinopharm Tech (08156) announced its interim results for the six months ending December 31, 2024. The group achieved a revenue of HK$18.89 million, representing a year-on-year increase of 0.29%. The company's shareholders' attributable loss was HK$5.513 million, an increase of 91.69% compared to the same period last year, with a basic loss per share of 2.17 HK cents. The group is continuing to focus on its supply chain business and health products as its main development direction. Leveraging its years of experience in supply chain services and cooperation with major platform operators, the group sees broad development opportunities in supply chain services and the health industry. The group is in discussions with product brand owners to expand its product supply list, preparing to increase marketing efforts and expand marketing channels, exploring the possibility of jointly developing new markets and seizing new development opportunities.